Global Sodium Heparin Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Sodium Heparin Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Heparin, also known as unfractionated heparin (UFH), is medication which is used as an anticoagulant (blood thinner). Specifically it is used to treat and prevent deep vein thrombosis, pulmonary embolism, and arterial thromboembolism. It is also used in the treatment of heart attacks and unstable angina.[3] It is given by injection into a vein.Other uses include inside test tubes and kidney dialysis machines.Common side effects include bleeding, pain at the injection site, and low blood platelets.Serious side effects include heparin induced thrombocytopenia. Greater care is needed in those with poor kidney function.Heparin appears to be relatively safe for use during pregnancy and breastfeeding.Heparin is a naturally occurring glycosaminoglycan.

Market Overview:

The latest research study on the global Sodium Heparin market finds that the global Sodium Heparin market reached a value of USD 2706.9 million in 2022. It’s expected that the market will achieve USD 5210.3 million by 2028, exhibiting a CAGR of 11.53% during the forecast period.

Influence of COVID-19 Outbreak on Sodium Heparin Industry Development

COVID-19 has wreaked havoc on a global scale. It has locked millions of people in their homes around the world and forced many businesses to close. The Sodium Heparin industry has also been disrupted by the pandemic, mainly because of supply chain disruptions.
During the COVID-19 outbreak, API shortages were caused by production halts and labor shortages. Affected by the epidemic, flights between countries have been sharply reduced, and transportation quarantine and transportation control measures have been increased. As a result, international logistics has been limited, the transportation capacity has been seriously insufficient, the delivery time of API has been prolonged, and the freight cost has increased significantly, which is reflected in the shortage of API supply and the increase in price.
There is a growing international demand for some API, such as antiviral API, antibiotic API, antipyretic and analgesic API, vitamin API, and hormone API. Sodium Heparin Industry is not included in the five APIs, so there is no significant increase in demand. In addition, affected by the COVID-19, in the short term, Sanofi-aventis. Pfizer, G1axoSmithKline, LEO, Sandoz, Ratiopharm and ROVI, Standard Heparin Preparation, and Low Molecular Weight Heparin API enterprise are all likely to be discontinued.

Strength

Diverse distribution channel.
Excellent performance leads to large demand.
Prevent blood clotting in vivo and vitro.

Weakness

Fierce competition from huge companies and well-developed regions.
Unbalance development by region.

Opportunity

Development of economy and technology.
Higher-quality and healthier products.

Threat

Lack of manufacturer in some regions.
Strict governmental permission regulations.

Region Overview:

Geographically, Europe held the largest market share – 46.16% in 2022.

Company Overview:

Shenzhen Hepalink Pharmaceutical Co., Ltd. is one of the major players operating in the Sodium Heparin market, holding a share of 12.53% in 2023.

Shenzhen Hepalink Pharmaceutical Co., Ltd.

Shenzhen Hepalink Pharmaceutical Group Co.,Ltd. manufactures and distributes pharmaceutical products. The Company mainly produces heparin sodium active pharmaceutical ingredients.

Bioiberica S.A

Bioiberica is a global Life Science company committed to improving the health and well-being of people, animals and plants. Bioiberica S.A.is experts at identifying, extracting and developing animal-derived biomolecules, which are transformed into high quality products the pharmaceutical, nutraceutical, veterinary, feed and agricultural industries.

Segmentation Overview:

As for product types, the Anti-FIIa 150 IU/mg-190 IU/mg segment held the largest market share in 2022.

Application Overview:

By application, the Low Molecular Weight Heparin API segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Sodium Heparin market covered in Chapter 3:

Shenzhen Hepalink Pharmaceutical Co., Ltd.
Sanofi
Aspen Pharmacare Holdings Limited
Changzhou Qianhong Biopharma Co., Ltd.
Opocrin S.p.A.
Pfizer
Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd.
Bioiberica S.A.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Yantai Dongcheng Biochemicals Co., Ltd.

In Chapter 4 and Chapter 14.2, on the basis of types, the Sodium Heparin market from 2018 to 2029 is primarily split into:

Anti-Flla150 IU/mg-190 IU/mg
Anti-Flla ≥190 IU/mg

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Sodium Heparin market from 2018 to 2029 covers:

Standard Heparin Preparation
Low Molecular Weight Heparin API

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)